@prefix this: <http://purl.org/np/RA8FelCvPBxTggV1kWoWeWpAxMHigoTMJwbaz9-O2_B-g> .
@prefix sub: <http://purl.org/np/RA8FelCvPBxTggV1kWoWeWpAxMHigoTMJwbaz9-O2_B-g#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ntemplate: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  drugbank:DB00904 a biolink:Drug;
    rdfs:label "Ondansetron";
    biolink:category biolink:Drug .
  
  <http://purl.obolibrary.org/obo/DOID_1574> a biolink:Disease;
    rdfs:label "alcohol use disorder";
    biolink:category biolink:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_1574>;
    rdf:predicate biolink:treats;
    rdf:subject drugbank:DB00904;
    a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    rdfs:label "While alcohol induces an increase of dopamine, ondansetron reduces the release of the neurotransmitter by blocking the 5-HT3 receptors. Several studies investigated the effectiveness of ondansetron by dividing alcoholic individuals into two subgroups based on their genotype for the promoter region of the SLC6A4 gene coding for the serotonin transporter (5-HTTLPR L/S polymorphism). The study showed that the patients with the LL genotype treated with ondansetron responded better in terms of alcohol amount and days of abstinence, compared to the other subgroups. Based on these results, researchers have further investigated genotype LL carriers, by analyzing the role of a functional polymorphism of the SLC6A4 gene (rs1042173 [T/G] SNP). The result was that individuals who carry both 5-HTTLPR LL polymorphism and rs1042173 TT polymorphism, treated with ondansetron at the dosage of 0.5 mg/die, present a more effective response to the drug. Unfortunately, the sample of this exploratory study was too small to be validated.";
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    biolink:has_population_context sub:context;
    biolink:publications pmid:29912214;
    biolink:relation ncit:C94303 .
  
  sub:context a biolink:Cohort;
    rdfs:label "adults";
    biolink:category biolink:Cohort .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
    npx:hasSignature "Amf2NBNpvSMgD1GnrMQcNJ669LPBQoTJYYwl3ipoapQkPeN8/oq1blWCDCMjt5abhgU+qt3ZKJjPKiZv7ePNUwa5z2K9Qf52NWKRGq3ms8O9ItnTUFqeK8EDwfQGVS5cw2MFhU6HqMUHiBl1uDY83uSaNB4tYCQksQmasx04cjQ=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2022-09-16T11:54:31.167009"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-1501-1082;
    ntemplate:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
  
  biolink: pav:version "2.3.0" .
}